Kishor Zinzuvadia, MD
Psychiatry · Poughkeepsie, NYNPI 1275582165
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $412,058 of the $487,793 with a category attached, or 84.5%. 20 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 57.0% of the total. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,122 payments — averaging $434.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$278K
- Alkermes, Inc.$99K
- AbbVie$63K
- Otsuka America Pharmaceutical, Inc.$22K
- Neurocrine Biosciences, Inc.$8K
- Sunovion Pharmaceuticals Inc.$4K
- plus $14K from 14 others
What the payments were for
- Consulting fees$12,3603%
- Speaking & faculty fees$412,05884%
- Travel & lodging$33,4637%
- Food & beverage$29,8016%
- Education$1110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 351 | $278,067 |
| Alkermes, Inc. | 170 | $98,699 |
| AbbVie(2 entities) | 236 | $63,251 |
| Otsuka America Pharmaceutical, Inc. | 56 | $21,985 |
| Neurocrine Biosciences, Inc. | 23 | $7,537 |
| Sunovion Pharmaceuticals Inc. | 78 | $4,232 |
| Axsome Therapeutics, Inc. | 15 | $3,988 |
| Johnson & Johnson | 11 | $2,762 |
| E.r. Squibb & Sons, L.L.C. | 33 | $2,377 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $1,765 |
| Takeda Pharmaceuticals U.S.A., Inc. | 65 | $1,422 |
| Bausch Health US, LLC | 29 | $529 |
| Lundbeck LLC | 21 | $423 |
| Merck | 18 | $363 |
| Boehringer Ingelheim | 1 | $125 |
| Corium, LLC | 4 | $87 |
| Luye Pharma (USA) Ltd. | 2 | $55 |
| Shire North American Group Inc | 2 | $48 |
| Idorsia Pharmaceuticals US Inc | 1 | $45 |
| Avanir Pharmaceuticals, Inc. | 2 | $35 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$306,590
- UZEDY$213,207
- LYBALVI$78,030
- ARISTADA INITIO$76,648
- VRAYLAR$58,415
- Austedo XR$52,846
- ABILIFY MAINTENA$21,021
- INGREZZA$7,187
- AUSTEDO$5,126
- Auvelity$3,707
- SPRAVATO$2,604
- LATUDA$2,588
- CAPLYTA$1,625
- COBENFY$1,377
- REXULTI$979
- ABILIFY ASIMTUFII$249
- VIIBRYD$200
- INVEGA SUSTENNA$125
- INVEGA TRINZA$125
- OFEV$125
How this compares
$487,793 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 204 | $1,413,270 |
| UzedyRisperidone | 276 | $895,705 |
| VraylarCariprazine Hcl | 332 | $510,898 |
| RexultiBrexpiprazole | 234 | $374,461 |
| AristadaAripiprazole Lauroxil | 91 | $282,970 |
| Abilify MaintenaAripiprazole | 35 | $104,238 |
| VivitrolNaltrexone Microspheres | 59 | $99,486 |
| Clozapine | 519 | $60,030 |
| Quetiapine Fumarate | 1,125 | $47,106 |
| Aripiprazole | 481 | $41,160 |
| NuedextaDextromethorphan Hbr/Quinidine | 32 | $39,583 |
| Risperidone | 1,190 | $33,250 |
| Divalproex Sodium | 506 | $31,014 |
| Divalproex Sodium ErDivalproex Sodium | 244 | $29,180 |
| BelsomraSuvorexant | 63 | $28,499 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy | $278,067 | $2,308,975480 claims |
| AbbVieVraylar | $63,251 | $510,898332 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $21,985 | $478,699269 claims |
| Alkermes, Inc.Aristada, Vivitrol, Lybalvi | $98,699 | $405,310164 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $35 | $39,58332 claims |
| MerckBelsomra | $363 | $28,49963 claims |
| Johnson & JohnsonInvega Sustenna | $2,762 | $26,38111 claims |
| Lundbeck LLCOnfi | $423 | $12,24112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Poughkeepsie
- Leslie CitromePomona$5.7M
- Sanjay GuptaCheektowaga$1.9M
- Richard PriceMonsey$1.7M
- Adam AshtonAmherst$1.6M
- Christoph CorrellGlen Oaks$1.5M
- Manish ZinzuvadiaNew York$1.3M
- George KruseBronx$1.2M
- Jianping ChenNew York$1.2M
- Horacio CapoteAmherst$1.1M
- Yadagiri ChepuruYonkers$963K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.